TrialBlood2021

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.

Shuo Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.